References
- Schimpff S, Satterlee W, Young V M, Scrpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and grunulocytopenia. N Engl J Med 1971; 284: 1061–1065
- Pizzo P A. Empiric therapy and prevention of infection in the immunocompromised host. Principles and practice of infectious diseases, 2nd ed., G L Mandell, R G Douglas, Jr, J E Bennett. John Wiley, New York 1985; 1680–1688
- de Pauw B, Williams K, de Neeff J, Bothof T, de Witte T, Holdrinet R, Haanen C. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1985; 28: 824–828
- Verhagen C S, de Pauw B, de Witte T, Jansen J, Williams K, de Mulder P, Bothof T. Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1987; 31: 191–196
- Reilly J T, Brada M, Bellingham A J, Hart C A, Bennett C. Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patients. J Antimicrob Chemother 1983; 12(Suppl A)89–92
- Ramphal R, Kramer B S, Rand K H, Weiner R S, Shands J W, Jr. Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. J Antimicrob Chemother 1983; 12(Suppl A)81–88
- Donnelly J P, Marcus R E, Goldman J M, Cohen J, Worsley A M, Catovsky D, Darrell J H, Want S V, Galton D A. Ceftazidime as first-line therapy for fever in acute leukemia. J Infect 1985; 11: 205–215
- Pizzo P A, Hathorn J W, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, Rubin M, Skelton J, Thaler M, Wesley R. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–558
- Wade J C. Antibiotic therapy for the febrile granulocytopenic cancer patient: Combination therapy vs. monotherapy. Rev Infect Dis 1989; 11(Suppl 7)1572–1581
- Paul C, Tidefelt U, Gahrton G, Björkholm M, Järnmark M, Killander A, Kimby E, Lilliemark Lindeberg J A, Lindqvist R, Lockner D, Lönnqvist B, Mellstedt H, Merk K, Palmblad J, Peterson C, Simonsson B, Stalfelt A-M, Sundström C, Wadman B, Wedelin C, Udén A-M, Öberg G, Öst Å. A randomized comparison of doxorubicin and doxorubicin-DNA in the treatment of acute non-lymphoblastic leukemia. Leukemia and Lymphoma 1991; 3: 355–364
- Gale R P, Cline M J. High remission induction rate in acute leukemia. Lancet 1977; 1: 497–499
- Sanches-Fayos J, Outerino E, Villalobos E, Paniagua C, Calabuig T, Lite M, Perez-Figuera A., Rus G, Prieto E, Serrano Escudero J. A. Acute lymphoblastic leukemia in adults: results of a “totaltherapy” programme in 47 patients over 15 years old. Br J Haematol 1985; 59: 686–696
- From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161: 397–401
- Wade J C, Schimpff S C, Newman K A, Wiernick P H. Staphylococcus epidermidis; an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1982; 97: 503–508
- Johnson P RE, Liu Yin J A, Tooth J A. High dose intravenous ciprofloxacin in febrile neutropenic patients. J Antimicrob Chemother 1990; 26(Suppl F)101–107
- Nováková I, Donnelly P, de Pauw B. Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia. Scand J Infect Dis 1990; 22: 705–711